Charlie is currently the CSO of Affinia Therapeutics, a company devoted to developing the next generation of gene therapy by improved targeting of AAV. Prior to Affinia, Charlie was chief scientific officer at Editas Medicine where his research group advanced the pioneering CRISPR gene-editing platform and medicines from program inception to Investigational New Drug (IND) application. He has led research activities at both biotech and big pharma companies across a range of therapeutic areas, including neurology, neuromuscular, cardiovascular,...Read more
Presentation Abstract: Process Development is a key skill for industry in translating ideas and opportunities into commercial reality, including today’s grand challenges in achieving Net Zero...
